• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
PENG Siqi,SUN Long.Research status and progress on DNA Vaccines for chronic hepatitis B[J].Journal Of Pharmaceutical Research,2025,44(7):711-717[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2105times   Download 788次 QR Code for this article
Scan with your phone!
慢性乙型肝炎DNA疫苗的研究现状及进展
彭斯其,孙龙
Font:Larger+|Default|Smaller-
(海南医科大学第一附属医院感染科,海南 海口 570102)
摘要:
慢性乙型肝炎是由乙型肝炎病毒引起的慢性传染病,发病率高。目前的抗病毒治疗以传统肌肉注射药物为主,无法彻底清除病毒,且存在药物副作用、耐药及患者需长期或终生服药等局限性。而DNA疫苗作为一种新兴的治疗策略,因能同时诱导体液及细胞免疫反应及稳定性高的潜力而备受关注,并在临床前动物模型试验中展现了较好的结果。DNA疫苗可通过联合治疗、佐剂及电穿孔技术增强质粒DNA的摄取效率,从而显著增强疗效。本文综述了当前DNA疫苗在慢性乙型肝炎治疗中的研究进展,包括其作用机制、动物模型中的临床前研究、临床试验及未来的发展方向。
关键词:  DNA疫苗  乙型肝炎病毒  免疫治疗  电穿孔
DOI:10.13506/j.cnki.jpr.2025.07.013
基金项目:国家重点研发计划项目(No.2022YFC2305001)
Research status and progress on DNA Vaccines for chronic hepatitis B
PENG Siqi,SUN Long
(Department of Infectious Diseases, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, China)
Abstract:
Chronic hepatitis B (CHB) is a chronic infectious disease caused by the hepatitis B virus (HBV), with a high global prevalence. Current antiviral therapies primarily rely on traditional intramuscular injection drugs, which still face limitations such as incomplete viral clearance, drug side effects, drug resistance, and the need for long-term or lifelong medication. As an emerging therapeutic strategy, DNA vaccines have garnered significant attention due to their potential to simultaneously induce humoral and cellular immune responses and their high stability. Preclinical studies in animal models have demonstrated promising results. By combining adjuvants and electroporation techniques, the uptake efficiency of plasmid DNA can be enhanced, significantly improving therapeutic efficacy. Preliminary results from related clinical trials have also been encouraging. This review summarizes the current research progress of DNA vaccines in CHB treatment, including their mechanisms of action, preclinical studies in animal models, clinical trials, distinctions from RNA vaccines, and future development directions.
Key words:  DNA vaccines  Hepatitis B virus  Immunotherapy  Electroporation
Today's Visits:510    Total Visits:2383241
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.